Axsm stock

Axsm stock DEFAULT

Axsome TherapeuticsNasdaqGM:AXSM Stock Report

Price History & Performance

Historical stock prices
Current Share PriceUS$
52 Week HighUS$
52 Week LowUS$
1 Month Change%
3 Month Change%
1 Year Change%
3 Year Change%
5 Year Change%
Change since IPO%

Recent News & Updates

Sep 24

Axsome Therapeutics: Amid The FDA Difficulty Is A Huge Opportunity

Among various companies being negatively impacted by a hypersensitive FDA environment, Axsome Therapeutics shares recently tumbled. Amid the aforesaid debacle, AXS received a "stand by" notice from the FDA for its New Drug Application for major depressive disorder. Due to its superb therapeutic merits, AXS also posted strongly positive data for the highly difficult-to-manage indication of treatment-resistant depression.

Aug 15

Axsome: Is The Pullback A Buying Opportunity?

Axsome is down due to two adverse events. The first, rescinding of the BTD for AXS, is a non-event. The other one, potential delay with AXS's PDUFA, is a concern. Given the vast pipeline and the huge drop, however, this pullback is an excellent opportunity.

Shareholder Returns

AXSMUS PharmaceuticalsUS Market

Return vs Industry: AXSM underperformed the US Pharmaceuticals industry which returned % over the past year.

Return vs Market: AXSM underperformed the US Market which returned % over the past year.

Price Volatility

AXSM volatility
Industry Beta
Market Beta1

Stable Share Price: AXSM is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: AXSM's weekly volatility has increased from 11% to 17% over the past year.

About the Company

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS for the treatment of migraine; AXS for the treatment of narcolepsy; and AXS for the treatment of fibromyalgia.

Axsome Therapeutics Fundamentals Summary

AXSM fundamental statistics
Market CapUS$b
Earnings (TTM)-US$m
Revenue (TTM)n/a

Earnings & Revenue

AXSM income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$0

Last Reported Earnings

Jun 30,

Earnings per share (EPS)
Gross Margin%
Net Profit Margin%
Debt/Equity Ratio%

How did AXSM perform over the long term?

See historical performance and comparison


Is Axsome Therapeutics undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: AXSM ($) is trading below our estimate of fair value ($)

Significantly Below Fair Value: AXSM is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: AXSM is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: AXSM is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AXSM's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: AXSM is overvalued based on its PB Ratio (x) compared to the US Pharmaceuticals industry average (x).

Future Growth

How is Axsome Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AXSM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AXSM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AXSM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AXSM's revenue (% per year) is forecast to grow faster than the US market (% per year).

High Growth Revenue: AXSM's revenue (% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AXSM is forecast to be unprofitable in 3 years.

Past Performance

How has Axsome Therapeutics performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AXSM is currently unprofitable.

Growing Profit Margin: AXSM is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: AXSM is unprofitable, and losses have increased over the past 5 years at a rate of % per year.

Accelerating Growth: Unable to compare AXSM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXSM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (%).

Return on Equity

High ROE: AXSM has a negative Return on Equity (%), as it is currently unprofitable.

Financial Health

How is Axsome Therapeutics's financial position?

Financial Position Analysis

Short Term Liabilities: AXSM's short term assets ($M) exceed its short term liabilities ($M).

Long Term Liabilities: AXSM's short term assets ($M) exceed its long term liabilities ($M).

Debt to Equity History and Analysis

Debt Level: AXSM's debt to equity ratio (%) is considered high.

Reducing Debt: Insufficient data to determine if AXSM's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AXSM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AXSM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


What is Axsome Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AXSM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AXSM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AXSM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AXSM's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AXSM's dividend in 3 years as they are not forecast to pay a notable one for the US market.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January and has been its Chief Executive Officer, President and Chairman since January Dr. Tabuteau served as Interim Principal Fina

CEO Compensation Analysis

Compensation vs Market: Herriot's total compensation ($USDM) is above average for companies of similar size in the US market ($USDM).

Compensation vs Earnings: Herriot's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: AXSM's management team is considered experienced ( years average tenure).

Board Members

Experienced Board: AXSM's board of directors are considered experienced ( years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Axsome Therapeutics, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Axsome Therapeutics, Inc.
  • Ticker: AXSM
  • Exchange: NasdaqGM
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$b
  • Shares outstanding: m
  • Website:

Number of Employees


  • Axsome Therapeutics, Inc.
  • 22 Cortlandt Street
  • 16th Floor
  • New York
  • New York
  • United States


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis/10/20
End of Day Share Price/10/20
Annual Earnings/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Simply Wall Street Pty Ltd (ACN ), is a Corporate Authorised Representative (Authorised Representative Number: ) of Sanlam Private Wealth Pty Ltd (AFSL No. ). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.


Actual Analyst Range Consensus



AXSM will report FY earnings on 03/17/ AXSM will report Q3 earnings on 03/17/

Q3 Estimate Trends
1 month ago:$
3 months ago:$
Q4 Estimate Trends
1 month ago:$
3 months ago:$
FY Estimate Trends
1 month ago:$
3 months ago:$
FY Estimate Trends
1 month ago:$
3 months ago:$
 3 Months Ago1 Month AgoCurrent




















Current Price$
  1. Superhero teacher svg
  2. Pig oil mats
  3. Modern rag doll
  4. Brittany spaniel doodles

Axsome Therapeutics Inc Stock , AXSM

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS, AXS, AXS, and AXS which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, and is headquartered in New York, NY.


Moody’s Daily Credit Risk Score is a score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Ownerin %
Herriott Tabuteau, MD
The Vanguard Group, Inc.
Vanguard Group, Inc. (Subfiler)
Iridian Asset Management LLC
Iridian Asset Management LLC
RA Capital Management LP
RTW Investments LP
BlackRock Fund Advisors
Alethea Capital Management LLC
Venrock Associates
Vanguard Total Stock Market Index Fund
T. Rowe Price Associates, Inc. (Investment Management)
Vanguard Small Cap Index Fund
BlackRock Institutional Trust Co. NA

Shareholder percentage totals can add to more than % because some holders are included in the free float.

Axsome Therapeutics (AXSM): A 1360% Gainer With Unfolding Catalyst

Axsome Therapeutics Inc (NASDAQ:AXSM)

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC and/or its affiliates.

© Cable News Network. A Warner Media Company. All Rights Reserved.
CNN Sans™ & © Cable News Network.


Stock axsm

Oct AM  Oct AM  Oct AM  Oct AM  Oct AM  Oct AM  Sep PM  Sep AM  Sep PM  Sep AM  Sep AM  Sep AM  Sep AM  Sep AM  Sep PM  Sep PM  AM  Sep AM  Sep AM  Sep PM  Aug AM  Aug AM  AM  Aug PM  AM  AM  AM  Aug AM  AM  Aug AM  Aug PM  AM  Aug AM  AM  AM  Aug PM  AM  AM  AM  Aug PM  PM  AM  AM  Aug PM  PM  PM  PM  AM  AM  AM  AM  Aug AM  Jul AM  Jul PM  Jul PM  AM  Jul AM  Jul PM  Jul AM  Jul PM  AM  AM  Jul PM  PM  AM  Jun AM  Jun AM  Jun AM  Jun AM  AM  Jun AM  Jun AM  May AM  May PM  AM  AM  May AM  AM  Apr AM  Apr AM  Apr AM  Apr PM  PM  AM  AM  Apr AM  Apr PM  AM  Mar AM  Mar AM  Mar AM  Mar AM  Mar PM  AM  AM  Feb AM  Feb AM  Feb AM  Jan AM  Jan AM  
3 Stocks Ready To Explode!

Axsome Therapeutics Inc AXSM:NASDAQ


  • Open
  • Day High
  • Day Low
  • Prev Close
  • 52 Week High
  • 52 Week High Date12/22/20
  • 52 Week Low
  • 52 Week Low Date08/19/21
  • Market CapB
  • Shares OutM
  • 10 Day Average VolumeM
  • Dividend-
  • Dividend Yield-
  • Beta
  • YTD % Change


  • EPS (TTM)
  • P/E (TTM)
  • Fwd P/E (NTM)
  • ROE (TTM)%
  • Revenue (TTM)
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)%


  • Earnings Date11/03/
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

There is no recent news for this security.

There is no recent news for this security.


You will also be interested:

We become quiet. This someone slowly steps on the tiled floor, enters the next booth. Sayid and I exchange glances, and then he waves it off, and then everything happens in complete silence. Sayid's fly screeches, and a.

1365 1366 1367 1368 1369